Bladder cancer treatment theme cools down, breaking through support levels despite favorable news of expanded approval

Reviewing Prediction vs. Actual Result

I entered the stock anticipating a test of the resistance level ($10.81), trusting the clear positive catalyst of the expanded approval range for the immuno-oncology drug Anktiva, the moving averages in a bullish alignment, and a moderate upward momentum with an RSI of 62.5, but the result was a -13.9% loss and a FAILED judgment. My misjudgment lay in interpreting the subdued trading volume at entry—0.79 times the 20-day average—and the recent 7-day volatility of -4.7% indicating a short-term correction, as a healthy pullback digestion process. Although I set the support level at $7.76 on the downside, the actual share price failed to achieve the expected support bounce and trended downward, widening the loss. I confirmed that even though thematic news count was on an upward trend and the S-Class conversion rate reached 14.8%, it was insufficient to offset the weak supply and demand of the individual stock.

What to Watch in the Next Analysis

The failure of this trade stemmed from relying solely on positive news and technical indicators such as a bullish moving-average alignment (jeongbae-yeol), while underestimating the supply-demand vulnerability of volume falling below the 20-day average (0.79x). In future trades, rather than depending solely on the magnitude of news and the rising trend of a theme, I will apply an execution strategy of more conservatively postponing entry during consolidation phases lacking volume support, or setting tighter, shorter stop-loss criteria.